/GBIO
GBIO Stock - Generation Bio Co.
Healthcare|BiotechnologyNASDAQ
$5.54+1.65%
+$0.09 (+1.65%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.68
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).40
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.42
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-5.2%upside
Target: $5.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.48 – $5.60
TARGET (TP)$5.25
STOP LOSS$5.10
RISK/REWARD1:-0.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.96
52W High$12.50
52W Low$3.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $19.89M | $5.90M | N/A | N/A | N/A |
| Gross Profit | $19.89M | $5.90M | N/A | N/A | $-3,432,000 |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-142,390,000 | $-138,563,000 | $-141,182,000 | $-119,101,000 | $-81,114,000 |
| Net Income | $-131,668,000 | $-126,612,000 | $-136,639,000 | $-119,151,000 | $-80,523,000 |
| Net Margin | -661.9% | -2144.5% | N/A | N/A | N/A |
| EPS | $-19.76 | $-19.63 | $-23.51 | $-21.17 | $-29.54 |
Company Overview
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
50%
Hold / Neutral
2
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish2 Neutral/Bearish
Price Targets
$7
Average Target
↑ 19.6% Upside
Now
$5
Low
$7
Average
$9
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Wedbush | Upgrade | Outperform | $5.5 |
| December 16th 2025 | Jefferies | Downgrade | Hold | $5 |
| August 13th 2025 | Wedbush | Downgrade | Neutral | $7 |
| October 19th 2023 | TD Cowen | Downgrade | Market Perform | - |
| November 8th 2022 | Canaccord Genuity | Initiation | Buy | $9 |
Earnings History & Surprises
GBIOBeat Rate
44%
Last 18 quarters
Avg Surprise
-11.3%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.82
Q4 2025
EPS Surprise History
Q1 24
-29.3%
$-0.53vs$-0.41
Q2 24
-211.1%
$-1.12vs$-0.36
Q3 24
-14.8%
$-0.31vs$-0.27
Q4 24
+17.9%
$-0.23vs$-0.28
Q1 25
-14.3%
$-0.32vs$-0.28
Q2 25
+12.0%
$-2.20vs$-2.50
Q3 25
-11.4%
$-3.12vs$-2.80
Q4 25
+74.2%
$-0.82vs$-3.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | — | — | — | — |
Q4 2025 | Nov 5, 2025 | $-3.18 | $-0.82 | +74.2% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-2.80 | $-3.12 | -11.4% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-2.50 | $-2.20 | +12.0% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.28 | $-0.23 | +17.9% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.27 | $-0.31 | -14.8% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.36 | $-1.12 | -211.1% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.41 | $-0.53 | -29.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.51 | $-0.43 | +15.7% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.49 | $-0.47 | +4.1% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.39 | $-0.53 | -35.9% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.67 | $-0.53 | +20.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.63 | $-0.66 | -4.8% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.52 | $-0.61 | -17.3% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.57 | $-0.54 | +5.3% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.55 | $-0.56 | -1.8% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.47 | $-0.55 | -17.0% | ✗ MISS |
Latest News
Wedbush Upgrades Generation Bio to Outperform, Lowers Price Target to $5.5
📈 PositiveBenzinga•Dec 16, 2025, 01:54 PM
Jefferies Downgrades Generation Bio to Hold, Lowers Price Target to $5
📉 NegativeBenzinga•Dec 16, 2025, 01:08 PM•Also:
Trading Halt: Halt status updated at 5:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 15, 2025, 10:25 PM
XOMA Royalty To Acquire Generation Bio Co. For A Cash Price Of $4.2913 Per Share At The Closing Of The Merger
📈 PositiveBenzinga•Dec 15, 2025, 10:02 PM
Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 15, 2025, 09:55 PM
Generation Bio Q3 EPS $(0.82) Beats $(3.17) Estimate, Sales $1.594M Beat $660.000K Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:45 PM
Generation Bio President, CEO Geoff McDonough To Become Board Chair, Effective Oct. 31; Yalonda Howze Names Interim CEO, President
➖ NeutralBenzinga•Oct 22, 2025, 08:09 PM
Generation Bio soars as it explores strategic alternatives
📈 PositiveSeeking Alpha•Aug 13, 2025, 02:49 PM
Generation Bio Posts 81% Q2 Revenue Drop
📉 NegativeThe Motley Fool•Aug 13, 2025, 02:40 AM
Frequently Asked Questions about GBIO
What is GBIO's current stock price?
Generation Bio Co. (GBIO) is currently trading at $5.54 per share. The stock has moved +1.65% today.
What is the analyst price target for GBIO?
The average analyst price target for GBIO is $5.25, based on 1 analyst.
What sector is Generation Bio Co. in?
Generation Bio Co. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GBIO's market cap?
Generation Bio Co. has a market capitalization of $0.04 billion, making it a small-cap company.
Does GBIO pay dividends?
No, Generation Bio Co. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to GBIO for comparison